Metastatic Cancer Clinical Trials

83 recruiting

Metastatic Cancer Trials at a Glance

102 actively recruiting trials for metastatic cancer are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 1 with 40 trials, with the heaviest enrollment activity in Houston, New York, and Chicago. Lead sponsors running metastatic cancer studies include Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, and Fudan University.

Browse metastatic cancer trials by phase

Treatments under study

About Metastatic Cancer Clinical Trials

Looking for clinical trials for Metastatic Cancer? There are currently 83 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 102 trials

Recruiting
Phase 1

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Metastatic Cancer
University of California, Davis40 enrolled1 locationNCT06389123
Recruiting
Phase 1

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Metastatic CancerAdvanced CancerSolid Tumor
Jazz Pharmaceuticals332 enrolled15 locationsNCT05557045
Recruiting
Not Applicable

Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial

Metastatic Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's138 enrolled2 locationsNCT05508464
Recruiting
Not Applicable

A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.

Metastatic Cancer
Elsan35 enrolled1 locationNCT06363773
Recruiting
Phase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Gastric CancerMetastatic CancerAdvanced Cancer+1 more
Centre Leon Berard132 enrolled6 locationsNCT06346197
Recruiting
Phase 2

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

GISTGIST - Gastrointestinal Stromal TumorGastrointestinal Tumors+2 more
Kumquat Biosciences Inc.46 enrolled1 locationNCT07406633
Recruiting
Phase 1

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Breast CancerOvarian CancerCancer+4 more
Conjupro Biotherapeutics, Inc.386 enrolled5 locationsNCT07424547
Recruiting
Phase 2

Biomarkers to Detect Endocrine Therapy Resistance

Breast CancerMetastatic CancerLobular Breast Carcinoma
University of Wisconsin, Madison8 enrolled1 locationNCT06067503
Recruiting
Phase 1Phase 2

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Advanced Solid TumorMetastatic CancerCutaneous Melanoma
Aulos Bioscience, Inc.159 enrolled18 locationsNCT05267626
Recruiting
Not Applicable

Comparison of Whole Body DWI to FDG PET

Metastatic Cancer
University of California, San Francisco30 enrolled1 locationNCT06630845
Recruiting
Phase 1

Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

Metastatic CancerTumor
Yi Tian30 enrolled1 locationNCT07144085
Recruiting
Phase 3

Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases

Oligo-metastatic Cancer
Ming-Yuan Chen200 enrolled2 locationsNCT07481799
Recruiting
Phase 1Phase 2

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Recruiting

Optimizing Y90 Therapy for Radiation Lobectomy

Metastatic CancerHCCResection+2 more
Northwestern University104 enrolled2 locationsNCT04390724
Recruiting
Phase 1

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Metastatic Breast CancerEndometrial CancerAdvanced Solid Tumor+6 more
Institut Paoli-Calmettes27 enrolled1 locationNCT05143970
Recruiting
Early Phase 1

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Metastatic CancerCarcinomaAdenocarcinoma
Roberto Vargas4 enrolled1 locationNCT05065736
Recruiting
Phase 1Phase 2

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting
Phase 1

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

Metastatic Cancer
University of Wisconsin, Madison60 enrolled1 locationNCT07197671
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Not Applicable

Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services

Advanced CancerMetastatic Cancer (Different Solid Tumour Types)Palliative Care, Health Services+1 more
Dartmouth-Hitchcock Medical Center90 enrolled1 locationNCT07195513